Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03961295 · ClinicalTrials.gov registry record · Phase 1

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Takeda.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT03961295: Completed Phase 1 study of Healthy Volunteers, sponsored by Takeda.

NCT03961295 is a Phase 1 study of Healthy Volunteers that has completed, run by Takeda. The registered enrollment target is 24 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03961295, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.

Conditions Studied

Interventions

  • DRUG Vedolizumab SC

Study Locations (1)

Nebraska

  • Celerion - Lincoln

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2018-02-22
Est. Completion 2018-08-28
Phase Phase 1
Takeda

408 total trials

What the finished NCT03961295 record still lists

NCT03961295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which Vedolizumab SC is the first listed.

NCT03961295 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT03961295 about?

NCT03961295 is a clinical study titled "A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants". The purpose of this study is to compare PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.

What is the current status of trial NCT03961295?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-02-22. Estimated completion is 2018-08-28.

What conditions does trial NCT03961295 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT03961295?

The interventions under investigation include: Vedolizumab SC (DRUG).

Who is sponsoring clinical trial NCT03961295?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03961295 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03961295's enrollment target sits among peer trials

24 204th of 283 higher than 66 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03961295, the US trial registry maintained by the National Library of Medicine. NCT03961295 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.